Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial.

BACKGROUND Perioperative epirubicin, cisplatin and fluorouracil (ECF) chemotherapy improves survival in operable oesophago-gastric cancer [Adjuvant Gastric Cancer Infusional Chemotherapy (MAGIC) trial HR 0.75 (0.6-0.93)]. HER2 amplification is reported to predict enhanced benefit from anthracyclines in breast cancer. We sought to define whether HER2 predicts benefit from ECF in oesophago-gastric cancer. PATIENTS AND METHODS Diagnostic biopsies and/or resection specimens were collected from 415 of 503 MAGIC trial patients (82.5%). HER2 was evaluated by immunohistochemistry (IHC) and brightfield dual in situ hybridisation (BDISH) in tissue microarrays. The prognostic and predictive impact of HER2 status was investigated. RESULTS Concordance between HER2 over-expression (IHC3+) and amplification was 96%. Results of HER2 assessment in biopsy and resection specimens were concordant in 92.9% (145/156). HER2 positive rate (IHC3+, or IHC2+/BDISH positive) was 10.9% in the whole cohort and 10.4% in resection specimens. A further 4.0% of resections were IHC negative/BDISH positive. HER2 status was neither prognostic, nor (in pre-treatment biopsies) predicted enhanced benefit from chemotherapy [HER2 positive HR 0.74 (0.14-3.77); HER2 negative HR 0.58 (0.41-0.82), interaction P = 0.7]. However, the power of the predictive analysis was limited by the small number of HER2 positive pre-treatment biopsies. CONCLUSIONS HER2 status is not an independent prognostic biomarker in early oesophago-gastric adenocarcinoma.

[1]  Laura H. Tang,et al.  Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  H. Imamura,et al.  Impact of Expression of Human Epidermal Growth Factor Receptors EGFR and ERBB2 on Survival in Stage II/III Gastric Cancer , 2012, Clinical Cancer Research.

[3]  C. Thallinger,et al.  Her-2/neu gene amplification and over-expression in stomach and esophageal adenocarcinoma: from pathology to treatment. , 2012, Critical reviews in oncology/hematology.

[4]  Tsung-Teh Wu,et al.  Association of HER2/ErbB2 Expression and Gene Amplification with Pathologic Features and Prognosis in Esophageal Adenocarcinomas , 2012, Clinical Cancer Research.

[5]  C. Sotiriou,et al.  HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. , 2011, The Lancet. Oncology.

[6]  S. Nonogaki,et al.  Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  J. Pignon,et al.  Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  M. Buyse,et al.  Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  J. E. Boers,et al.  HER2 status in gastro-oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH) , 2011, Histopathology.

[10]  J. Nortier,et al.  Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer. , 2010, Cancer treatment reviews.

[11]  Yoon-Koo Kang,et al.  Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial , 2010, The Lancet.

[12]  Manfred Dietel,et al.  HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testing , 2010, Virchows Archiv.

[13]  H. Grabsch,et al.  HER2 Expression in Gastric Cancer: Rare, Heterogeneous and of No Prognostic Value – Conclusions from 924 Cases of Two Independent Series , 2010, Cellular oncology : the official journal of the International Society for Cellular Oncology.

[14]  D. Hwang,et al.  Gastrosplenic fistula from Hodgkin's lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  E. Van Cutsem,et al.  Pathological features of advanced gastric cancer (GC): Relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  R. Prescott,et al.  Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Robin L. Jones,et al.  Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients , 2008, Breast Cancer Research and Treatment.

[18]  T. Henkel,et al.  Assessment of a HER2 scoring system for gastric cancer: results from a validation study , 2008, Histopathology.

[19]  F. O'Malley,et al.  HER2/neu in systemic therapy for women with breast cancer: a systematic review , 2008, Breast Cancer Research and Treatment.

[20]  M. Sormani,et al.  HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. , 2008, Journal of the National Cancer Institute.

[21]  C. V. D. van de Velde,et al.  Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. , 2006, The New England journal of medicine.

[22]  Jens Overgaard,et al.  retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  for the Statistics Subcommittee of the NCI—EORTC Worki Diagnostics.  REporting recommendations for tumor MARKer prognostic studies (REMARK) , 2005, Nature Clinical Practice Oncology.

[24]  J. Isola,et al.  Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  M. Risio,et al.  HER2 testing in gastric cancer: molecular morphology and storage time-related changes in archival samples. , 2003, International journal of oncology.

[26]  L. David,et al.  c-erb B-2 Expression Is Associated with Tumor Location and Venous Invasion and Influences Survival of Patients with Gastric Carcinoma , 2002, International journal of surgical pathology.

[27]  M. Sehested,et al.  Culprit and victim -- DNA topoisomerase II. , 2002, The Lancet. Oncology.

[28]  H. Allgayer,et al.  c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  T. Järvinen,et al.  Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer. , 1998, British journal of cancer.

[30]  J. R. Landis,et al.  The measurement of observer agreement for categorical data. , 1977, Biometrics.

[31]  Alan Mackay,et al.  Evaluation of Phi29-based whole-genome amplification for microarray-based comparative genomic hybridisation , 2007, Laboratory Investigation.

[32]  T. Yano,et al.  Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. , 2006, Oncology reports.

[33]  Cdm Fletcher,et al.  World Health Organization Classification of Tumours , 2002 .

[34]  L. Aaltonen,et al.  Pathology and genetics of tumours of the digestive system , 2000 .